SMNR
What one share of Semnur Pharmaceuticals holds
Pharmaceutical Preparations
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives.
Semnur Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.76 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.03 |
| Book value | −$0.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.02 | — | −$0.02 | — | −$0.21 |
| 2025 | — | −$0.78 | — | −$0.03 | — | −$0.09 |